EP0787182A2 - Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung - Google Patents
Embryonale herzmuskelzellen, ihre herstellung und ihre verwendungInfo
- Publication number
- EP0787182A2 EP0787182A2 EP95940117A EP95940117A EP0787182A2 EP 0787182 A2 EP0787182 A2 EP 0787182A2 EP 95940117 A EP95940117 A EP 95940117A EP 95940117 A EP95940117 A EP 95940117A EP 0787182 A2 EP0787182 A2 EP 0787182A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- muscle cells
- cells
- genes
- heart muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 claims abstract description 9
- 239000003550 marker Substances 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims abstract description 8
- 230000004927 fusion Effects 0.000 claims abstract description 7
- 238000012546 transfer Methods 0.000 claims abstract description 7
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 claims abstract description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 6
- 210000004165 myocardium Anatomy 0.000 claims abstract description 6
- 229930193140 Neomycin Natural products 0.000 claims abstract description 5
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 229960004927 neomycin Drugs 0.000 claims abstract description 5
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 4
- 241000700584 Simplexvirus Species 0.000 claims abstract description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims abstract description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims abstract description 4
- 230000008828 contractile function Effects 0.000 claims abstract description 3
- 238000011835 investigation Methods 0.000 claims abstract description 3
- 108010065781 myosin light chain 2 Proteins 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 230000006801 homologous recombination Effects 0.000 claims abstract 2
- 238000002744 homologous recombination Methods 0.000 claims abstract 2
- 239000013598 vector Substances 0.000 claims description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 12
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000002574 poison Substances 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 108700005077 Viral Genes Proteins 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 210000002064 heart cell Anatomy 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 2
- 239000013605 shuttle vector Substances 0.000 claims description 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 101710109784 Myosin regulatory light chain 12B Proteins 0.000 claims 1
- 101710092698 Myosin regulatory light chain 2 Proteins 0.000 claims 1
- 101710112127 Myosin regulatory light chain 2, skeletal muscle isoform Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000002242 embryoid body Anatomy 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001625 cardiomyogenic effect Effects 0.000 description 1
- 230000001756 cardiomyopathic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000014471 histiocytoid cardiomyopathy Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4441327A DE4441327C1 (de) | 1994-11-22 | 1994-11-22 | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung |
DE4441327 | 1994-11-22 | ||
PCT/DE1995/001699 WO1996016163A2 (de) | 1994-11-22 | 1995-11-21 | Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0787182A2 true EP0787182A2 (de) | 1997-08-06 |
Family
ID=6533720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95940117A Withdrawn EP0787182A2 (de) | 1994-11-22 | 1995-11-21 | Embryonale herzmuskelzellen, ihre herstellung und ihre verwendung |
Country Status (4)
Country | Link |
---|---|
US (1) | US5928943A (de) |
EP (1) | EP0787182A2 (de) |
DE (1) | DE4441327C1 (de) |
WO (1) | WO1996016163A2 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
EP0862644A2 (de) * | 1995-11-17 | 1998-09-09 | Franz, Wolfgang-M., Dr. | Gentherapeutisches nukleinsäurekonstrukt, seine herstellung und verwendung zur behandlung von herzerkrankungen |
US6102926A (en) | 1996-12-02 | 2000-08-15 | Angiotrax, Inc. | Apparatus for percutaneously performing myocardial revascularization having means for sensing tissue parameters and methods of use |
US6051008A (en) | 1996-12-02 | 2000-04-18 | Angiotrax, Inc. | Apparatus having stabilization members for percutaneously performing surgery and methods of use |
US6120520A (en) | 1997-05-27 | 2000-09-19 | Angiotrax, Inc. | Apparatus and methods for stimulating revascularization and/or tissue growth |
EP1064356A2 (de) * | 1998-03-23 | 2001-01-03 | ZymoGenetics, Inc. | Herz-derivierte stammzellen |
US20030113301A1 (en) * | 1999-07-23 | 2003-06-19 | Albert Edge | Muscle cells and their use in cardiac repair |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US8075881B2 (en) | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
DE10014690A1 (de) * | 2000-03-24 | 2001-10-18 | Franz Wolfgang M | Verfahren zur Isolierung in vito differenzierter Körperzellen |
US7686799B2 (en) | 2000-07-13 | 2010-03-30 | Abbott Cardiovascular Systems Inc. | Deployment system for myocardial cellular material |
US7862810B2 (en) * | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
US20040096432A1 (en) * | 2000-12-27 | 2004-05-20 | Bernd Fleischmann | System for the cell-specific and development-specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
DE10136702B4 (de) | 2000-12-27 | 2004-04-22 | Axiogenesis Ag | System zur zell- und entwicklungsspezifischen Selektion differenzierender embryonaler Stammzellen, adulter Stammzellen und embryonaler Keimbahnzellen |
EP1367899A4 (de) | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotente adulte stammzellen, ausgangsmaterial dafür, verfahren zu ihrer gewinnung und erhaltung, differenzierungsmethoden dafür, verfahren zu ihrer verwendung, sowie von ihnen stammende zellen |
WO2003001202A1 (en) * | 2001-06-25 | 2003-01-03 | Cardion Ag | Methods and cell populations for identifying and validating genomic targets, and for drug screening |
US7732199B2 (en) | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
JP2004535199A (ja) * | 2001-07-12 | 2004-11-25 | ジェロン コーポレイション | ヒト多能性幹細胞から産生される心筋細胞系譜の細胞 |
WO2003014361A1 (en) * | 2001-08-02 | 2003-02-20 | Altana Pharma Ag | Novel recombinant gene expression method by stop codon suppression |
DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
US6893431B2 (en) | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US8574195B2 (en) * | 2002-06-10 | 2013-11-05 | Advanced Cardiovascular Systems, Inc. | Systems and methods for detecting tissue contact and needle penetration depth using static fluid pressure measurements |
US7364567B2 (en) | 2002-06-10 | 2008-04-29 | Abbott Cardiovascular Systems Inc. | Systems and methods for detecting tissue contact and needle penetration depth |
NZ537245A (en) * | 2002-07-26 | 2010-04-30 | Wisconsin Alumni Res Found | Method of testing cardiomyocytes derived from human embryonic stem cells formed in embryoid bodies differentiated into all of the major cardiac muscle cell types, including ventricular, atrial, and nodal cells |
JP2005534430A (ja) * | 2002-08-06 | 2005-11-17 | ジェンベック, インコーポレイテッド | 改良された注射システム |
JP2004246317A (ja) * | 2002-12-20 | 2004-09-02 | Hitachi Ltd | 冷陰極型フラットパネルディスプレイ |
JP4904153B2 (ja) | 2003-06-20 | 2012-03-28 | アキシオジェネシス エージー | 胚性幹(es)細胞系での組織モデリング |
WO2005003320A2 (en) * | 2003-07-02 | 2005-01-13 | Regents Of The University Of Minnesota | Neuronal differentiation of stem cells |
US8308708B2 (en) | 2003-07-15 | 2012-11-13 | Abbott Cardiovascular Systems Inc. | Deployment system for myocardial cellular material |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7452718B2 (en) * | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
US20050214938A1 (en) * | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
EP1740945B1 (de) | 2004-04-07 | 2018-09-19 | Ncardia AG | Nichtinvasive, in-vitro-funktionelle gewebetestsysteme |
WO2005108598A1 (en) | 2004-05-11 | 2005-11-17 | Axiogenesis Ag | Assay for drug discovery based on in vitro differentiated cells |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
KR101529317B1 (ko) | 2005-06-22 | 2015-06-16 | 아스테리아스 바이오세라퓨틱스, 인크. | 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화 |
US9005964B2 (en) * | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
KR20110005682A (ko) | 2008-01-30 | 2011-01-18 | 제론 코포레이션 | 줄기 세포 유래 심근세포 배양용 합성 표면 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5275942A (en) * | 1991-12-16 | 1994-01-04 | The University Of North Carolina At Chapel Hill | Mammalian cell-based DNA libraries |
-
1994
- 1994-11-22 DE DE4441327A patent/DE4441327C1/de not_active Expired - Fee Related
-
1995
- 1995-11-21 WO PCT/DE1995/001699 patent/WO1996016163A2/de active Application Filing
- 1995-11-21 EP EP95940117A patent/EP0787182A2/de not_active Withdrawn
- 1995-11-21 US US08/849,706 patent/US5928943A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
See references of WO9616163A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO1996016163A3 (de) | 1996-07-18 |
DE4441327C1 (de) | 1995-11-09 |
WO1996016163A2 (de) | 1996-05-30 |
US5928943A (en) | 1999-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4441327C1 (de) | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung | |
DE69937347T2 (de) | Regulierung der hämatopoietischen stammzelldifferenzierung durch verwendung von menschlichen mesenchymalen stammzellen | |
EP1948789B1 (de) | Verfahren zur herstellung von permanenten humanen zelllinien | |
DE60020855T2 (de) | Bedingte immortalisierung von zellen | |
DE60033663T2 (de) | Verfahren zur herstellung einer nicht-differenzierten kultur von vogelzellen mittels primordialer keimzellen | |
Dribin et al. | Conditioned medium enhances neuritic outgrowth from rat spinal cord explants | |
DE69831957T3 (de) | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen | |
DE69937243T2 (de) | Überexpression von gewünschten proteinen in eukaryotischen zellen mittels überexpression von cyclin d1 | |
AU2002330465B2 (en) | Screening method for a reprogramming agent, reprogramming agent screened by the method, method for using the reprogramming agent, method for differentiating an undifferentiated fusion cell, and production method of cells, tissues and organs. | |
WO2006044492A2 (en) | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome | |
EP0263908B1 (de) | Verfahren zur Herstellung von Proteinen mittels induzierbarer Expressionssysteme in in-vivo-vermehrten, genetisch modifizierten eukaryotischen Wirtszellen | |
WO1999001552A1 (de) | Fluoreszierende proteine als zelltypspezifische reporter | |
JPH11507230A (ja) | 細胞の不死化及び脱不死化 | |
DE69736858T2 (de) | Unsterbliche vogelzellen | |
DE69731310T2 (de) | Verfahren zum unsterblich machen von zellen | |
DE60021404T2 (de) | System zur herstellung von proteinen | |
DE60208066T2 (de) | Promotoren zur kontrolle der zelldifferenzierung | |
Hashimoto et al. | Cooperative transcription activation between Ad1, a CRE-like element, and other elements in the CYP11B gene promoter | |
WO1994016065A1 (en) | Producing cells for transplantation to reduce host rejection and resulting cells | |
DE69836853T2 (de) | Etablierte Mikrogliazellen | |
Thi et al. | Proliferation and differentiation properties of permanent Schwann cell lines immortalized with a temperature-sensitive oncogene | |
DE19716098A1 (de) | Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden | |
WO2002009507A1 (de) | Somatischer klonierungs-gentransfer zur produktion von rekombinanten proteinen, zellen und organen | |
US20030109037A1 (en) | Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease | |
JP2023515174A (ja) | 網膜色素上皮細胞の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970530 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010409 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CARDION AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSTITUT FUER PFLANZENGENETIK UND KULTURPFLANZENF |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAA | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOS REFN |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
17Q | First examination report despatched |
Effective date: 20010409 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LEIBNIZ-INSTITUT FUER PFLANZENGENETIK UND KULTURPF |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070712 |